| Balance Sheets | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 983 | 198 | 434 | 334 |
| Accounts receivable | 242 | 252 | 389 | 474 |
| Inventories, net | 232 | 244 | 237 | 141 |
| Restricted cash | 75 | 75 | 75 | 75 |
| Prepaid expenses | 17 | 10 | 41 | 23 |
| Total current assets | 1,549 | 779 | 1,176 | 1,047 |
| Property, plant and equipment, net | 9 | 9 | 10 | 11 |
| Total assets | 1,558 | 788 | 1,186 | 1,058 |
| Accounts payable | 719 | 767 | 879 | 784 |
| Convertible notes payable to related parties, current | 2,754 | 2,139 | 2,104 | NaN |
| Accrued liabilities | 181 | 149 | 176 | 154 |
| Total current liabilities | 3,654 | 3,055 | 3,159 | 938 |
| Convertible notes payable to related parties, non-current | 3,743 | 4,006 | 3,573 | 5,236 |
| Total liabilities | 7,397 | 7,061 | 6,732 | 6,174 |
| Common stock, 0.01 par value 200,000,000 shares authorized, 130,017,569 shares issued and outstanding at april 30, 2026, and 111,886,473 at july 31, 2025 | 1,301 | 1,119 | 1,119 | 1,119 |
| Additional paid-in capital | 133,727 | 132,851 | 132,793 | 132,759 |
| Accumulated deficit | -140,867 | -140,243 | -139,458 | -138,994 |
| Total stockholders deficiency | -5,839 | -6,273 | -5,546 | -5,116 |
| Total liabilities and stockholders deficiency | 1,558 | 788 | 1,186 | 1,058 |
PURE BIOSCIENCE, INC. (PURE)
PURE BIOSCIENCE, INC. (PURE)